Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension


AYPAR E. , ALEHAN D. , KARAGÖZ T. , AYKAN H. H. , ERTUĞRUL İ.

CARDIOLOGY IN THE YOUNG, cilt.28, sa.4, ss.542-547, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 28 Konu: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1017/s1047951117002542
  • Dergi Adı: CARDIOLOGY IN THE YOUNG
  • Sayfa Sayıları: ss.542-547

Özet

Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.